Expert Review of Anticancer Therapy This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Immunotherapy in urothelial cancer: current status and future directions
Expert Rev Anticancer Ther. 2023 Sep 29. doi: 10.1080/14737140.2023.2265572. Online ahead of print.ABSTRACTINTRODUCTION: Since 2016, the progressive use of immune checkpoint inhibitors (ICIs) starting from second-line treatment has led to an improvement in overall survival in locally advanced and metastatic urothelial cancer (UC). Clinical trials are underway testing the role of ICIs since the first stages of the disease, alone or in combination with standard therapies.AREAS COVERED: This review summarizes the current updated evidence regarding the role of ICIs in the different stages of UC, the ongoing clinical trials exp...
Source: Expert Review of Anticancer Therapy - September 29, 2023 Category: Cancer & Oncology Authors: Claudia Piombino Elena Tonni Marco Oltrecolli Marta Pirola Stefania Pipitone Cinzia Baldessari Massimo Dominici Roberto Sabbatini Maria Giuseppa Vitale Source Type: research

Selective multimodal bladder-sparing therapy for muscle-invasive bladder cancer: the present and the future
This article reviews major studies of selective, bladder-sparing therapy utilizing multiple modalities for muscle-invasive bladder cancer and those comparing the oncological outcomes between bladder-sparing therapy and radical cystectomy. Also discussed are predictive biomarkers potentially capable of guiding treatment decisions by patients with muscle-invasive bladder cancer and a novel strategy for boosting the antitumor immune response in bladder-sparing therapy. PubMed databases were searched for records of 30 June 2023 or earlier.EXPERT OPINION: Selective, bladder-sparing therapy appears to be underutilized at present...
Source: Expert Review of Anticancer Therapy - September 27, 2023 Category: Cancer & Oncology Authors: Fumitaka Koga Source Type: research

Locoregional recurrence in triple negative breast cancer: past, present, and future
Expert Rev Anticancer Ther. 2023 Sep 26. doi: 10.1080/14737140.2023.2262760. Online ahead of print.ABSTRACTINTRODUCTION: Triple negative breast cancer (TNBC) is a rare but aggressive biological subtype of breast cancer associated with higher locoregional and distant recurrence rates and lower overall survival despite advancements in diagnostic and treatment strategies.AREAS COVERED: This review explores the evolving landscape of locoregional recurrence (LRR) in TNBC with improved surgical and radiation therapy delivery techniques including salvage breast conserving surgery (SBCS), re-irradiation, and thermo-radiation. We r...
Source: Expert Review of Anticancer Therapy - September 26, 2023 Category: Cancer & Oncology Authors: Jennifer Tran Arushi Thaper Nerea Lopetegui-Lia Azka Ali Source Type: research

The long and winding road of fecal microbiota transplants to targeted intervention for improvement of immune checkpoint inhibition therapy
Expert Rev Anticancer Ther. 2023 Sep 25. doi: 10.1080/14737140.2023.2262765. Online ahead of print.ABSTRACTINTRODUCTION: Immune checkpoint inhibition (ICI) therapy has revolutionized the treatment of cancer. The principle of this treatment is that inhibitory molecules, either on the tumor or on cells of the immune system, are blocked by antibodies. The immune system of the patient subsequently should be able to attack and eradicate the tumor. Not all patients respond to ICI therapy, and response or non-response has been associated with composition of gut microbiota.AREA COVERED: Fecal microbiota transplantation (FMT) is us...
Source: Expert Review of Anticancer Therapy - September 25, 2023 Category: Cancer & Oncology Authors: Jasmijn Verhoef Ediz Klont Frans J van Overveld Ger T Rijkers Source Type: research

Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer
Expert Rev Anticancer Ther. 2023 Sep 25. doi: 10.1080/14737140.2023.2262764. Online ahead of print.ABSTRACTINTRODUCTION: Immune checkpoint inhibitors have been particularly effective in treating cancers with robust immune microenvironments and have been successfully incorporated into the management of metastatic ER-negative, HER2-negative breast cancer. This has prompted investigation of immunotherapy in early-stage triple negative breast cancer (TNBC) to address the suboptimal clinical outcomes and limited therapeutic options.AREAS COVERED: This review highlights the studies examining the use of neoadjuvant immunotherapy ...
Source: Expert Review of Anticancer Therapy - September 25, 2023 Category: Cancer & Oncology Authors: Ahmed Mohamed Megan Kruse Jennifer Tran Source Type: research

The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan
Expert Rev Anticancer Ther. 2023 Sep 24:1-9. doi: 10.1080/14737140.2023.2257885. Online ahead of print.ABSTRACTINTRODUCTION: Metastatic triple-negative breast cancer (TNBC) is an aggressive sub-type of breast cancer. Despite recent advances, metastatic TNBC remains difficult to treat with limited targeted treatment options. Fam-trastuzumab deruxtecan (T-DXd), is a novel antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2) and is composed of a unique linker bound to the topoisomerase I inhibitor DXd. T-DXd has significant anti-tumor activity in patients with HER2-low TNBC.AREAS COVERED: Th...
Source: Expert Review of Anticancer Therapy - September 24, 2023 Category: Cancer & Oncology Authors: Anna R Schreiber Cindy L O'Bryant Peter Kabos Jennifer R Diamond Source Type: research

Pediatric cancer care management during the COVID-19 pandemic: a review of the literature and a single-centre real-life experience of an Italian pediatric oncology unit
In conclusion, we reported the real-life experience of our pediatric oncology unit during the pandemic period.EXPERT OPINION: Starting from the data available in literature, and our experience, showing the rarity of severe COVID-19 disease in pediatric patients with solid tumors, we recommend carefully tailoring all the oncological treatments (chemotherapy/targeted therapy/stem cell transplantation/radiotherapy). The aim is the preservation of the treatment's timing, balanced with an evaluation of possible severe COVID-19 disease.PMID:37712347 | DOI:10.1080/14737140.2023.2245148 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - September 15, 2023 Category: Cancer & Oncology Authors: Olga Nigro Chiara Oltolini Federica Barzaghi Caterina Uberti Foppa Maria Pia Cicalese Maura Massimino Elisabetta Schiavello Source Type: research